Wnt9b-dependent FGF signaling is crucial for outgrowth of the nasal and maxillary processes during upper jaw and lip development

Yong-Ri Jin¹, Xiang Hua Han¹, Makoto M. Takeko² and Jeong Kyo Yoon¹,*

SUMMARY
Outgrowth and fusion of the lateral and medial nasal processes and of the maxillary process of the first branchial arch are integral to lip and primary palate development. Wnt9b mutations are associated with cleft lip and cleft palate in mice; however, the cause of these defects remains unknown. Here, we report that Wnt9b−/− mice show significantly retarded outgrowth of the nasal and maxillary processes due to reduced proliferation of mesenchymal cells, which subsequently results in a failure of physical contact between the facial processes that leads to cleft lip and cleft palate. These cellular defects in Wnt9b−/− mice are mainly caused by reduced FGF family gene expression and FGF signaling activity resulting from compromised canonical WNT/β-catenin signaling. Our study has identified a previously unknown regulatory link between WNT9B and FGF signaling during lip and upper jaw development.

KEY WORDS: WNT, β-Catenin, FGF signaling, Orofacial morphogenesis, Cleft lip, Cleft palate, Mouse

INTRODUCTION
Upper lip and nose development in mice starts around embryonic day (E) 9.5, when neural crest cells from the dorsal region of the fore- and mid-brain migrate ventrally and form mesenchyme within an unpaired frontonasal prominence rostral to the telencephalon (Serbedzija et al., 1992; Osumi-Yamashita et al., 1994; Kontges and Lumsden, 1996; Creuzet et al., 2005; Minoux and Rijli, 2010). In parallel, maxillary processes (MxPs) derived from the first branchial arch (BA1) become evident lateral to the stomodeum and rostral to the mandibular processes (MdxPs). At E10, within the ventrolateral region of the frontonasal prominence, the medial nasal (MNP) and lateral nasal (LNP) processes bulge and outgrow around the periphery of the nasal placode in a horseshoe shape, forming the nasal pit. In the E10.5 mouse embryo, mesenchymal cells within the MNP, LNP and MxP divide rapidly (Jiang et al., 2006). The lateral growth of the MxP pushes the nasal pits toward the middle face region. The ventral tip of the MNP extends further rostrally and ventrolaterally to begin fusion with both the LNP and the MxP at the medial end of their boundary junction. During fusion of these processes, apoptosis of epithelial cells occurs in the seam of the contacting MNP and LNP, resulting in the connection of mesenchymal cell compartments. By E11.5, the nostrils and lip are correctly formed by the completion of fusion of the MNP, LNP and MxP (Jiang et al., 2006; Song et al., 2009). In addition, the expanding MxP pushes the nostrils into the more medial region. Failure or delay of outgrowth and fusion of the NPs and MxP lead to cleft lip with or without cleft palate (CL/P) (Szabo-Rogers et al., 2010; Dixon et al., 2011).

The significance of the WNT signaling pathway in regulating facial morphogenesis is suggested by expression of various WNT ligand genes within the facial prominences (Summerhurst et al., 2008; Geetha-Loganathan et al., 2009). Canonical WNT signaling reporter transgenes such as TopGAL, BATgal and Axin2-lacZ are highly expressed in the facial prominences and their derivatives, further indicating a potential role of WNT/β-catenin signaling during facial development (Maretto et al., 2003; Brugmann et al., 2007; Al Alam et al., 2011). Previous studies of genetically altered mice in which the key components of WNT signaling are disrupted further suggest the crucial roles of WNT signaling in facial development. For instance, ablation of the canonical WNT signaling receptor gene Lrp6 causes hypoplasia of the facial processes accompanied by reduced cell proliferation within the NPs and CL/P in mice (Song et al., 2009). These mutant mice display severely reduced WNT/β-catenin signaling activity and decreased expression of the WNT target genes Msx1 and Msx2 within the facial processes. Both inactivation and constitutive activation of Ctnnb1, which encodes β-catenin, a central mediator of canonical WNT signaling, in the embryonic facial domains result in severe facial defects (Braut et al., 2001; Reid et al., 2011; Wang et al., 2011). Facial ectoderm-specific deletion or activation of Ctnnb1 result in downregulation or upregulation, respectively, of ectodermal FGF family gene expression, showing that canonical WNT signaling controls ectoderm FGF signaling during facial development (Reid et al., 2011; Wang et al., 2011). Mice lacking the R-spondin 2 (Rspo2) gene, which encodes a novel WNT agonist, exhibit hypoplasia and disrupted patterning of the MdxP, and cleft of the secondary palate with very low penetrance of cleft lip (Yamada et al., 2009; Jin et al., 2011).

Among the WNT genes expressed in the facial prominences, the developmental function of the individual genes and their association with craniofacial abnormalities including CL/P are not fully understood (Menezes et al., 2010). Wnt3 and Wnt9b are suggested to play roles in CL/P. Homozygous WNT3 mutation in humans is associated with CL/P (Niemann et al., 2004). The
association of Wnt9b with CL/P arises from the study of A/WySn mice. Approximately 5-30% of A/WySn mice display CL/P and the two genetic loci, cfl1 and cfl2, have been identified by linkage to CL/P. The cfl1 locus is located in the proximity of Wnt9b (Juriloff et al., 2005). By genetic complementation, A/WySn mice were confirmed to be homozygous for a hypomorphic Wnt9b allele (Juriloff et al., 2006). Consistent with the A/WySn study, Wnt9b null mice also show a higher frequency of CL/P than A/WySn mice (Juriloff et al., 2006). However, the nature of the embryological defects in Wnt9b null mice that lead to CL/P and the mechanism by which Wnt9b regulates the morphogenesis of facial structures during embryogenesis remain unknown.

In the present study, we investigated facial morphogenesis in Wnt9b null embryos. We found that loss of the Wnt9b gene caused retarded outgrowth and failed contact of the NPs and MxP, resulting in CL/P at a later stage. These defects were a direct consequence of reduced cell proliferation without any notable increase of cell apoptosis within mesenchymal cells of the NPs and MxP. Furthermore, these defects were associated with downregulation of FGF signaling, which acts as a mitogenic signal for mesenchymal cells in the NPs and MxP, as a result of compromised WNT/β-catenin signaling in Wnt9b−/− embryos. Our findings have identified a previously unknown role of Wnt9b in regulating the proliferation of NP and MxP mesenchymal cells by positively modulating ectoderm-derived FGF signaling.

MATERIALS AND METHODS

Animals
Mice carrying the Wnt9b conditional null (Wnt9b conditional null) allele (Carroll et al., 2005) in a genetic background outcrossed with Swiss Webster were kindly provided by Thomas J. Carroll (University of Texas Southwestern Medical Center). We crossed these mice with C57BL/6 mice once and the offspring were maintained in the mixed genetic background. A null allele of Wnt9b was generated by crossing Wnt9b−/− mice with CMV-Cre transgenic mice (Nagy et al., 1998). TopGal (DasGupta and Fuchs, 1999) and Foxg1 Cre mice (Hebert and McConnell, 2000) were obtained from The Jackson Laboratory. Ctnnb1 Cre mice carrying a conditional allele of constitutively active β-catenin (Harada et al., 1999) was obtained from Terry Yamaguchi (National Cancer Institute-Frederick). Mice were genotyped by PCR as described (Hebert and McConnell, 2000; Dunty et al., 2008; Jin et al., 2011). For in vivo activation of WNT/β-catenin signaling, 60 µl 300 mM LiCl or control 300 mM NaCl solution were intraperitoneally injected into pregnant females consecutively at gestation days 8.5, 9.5 and 10 before harvesting embryos at E10.5. Mice were housed in a pathogen-free air barrier facility. Animal handling and procedures were approved by the Maine Medical Center Institutional Animal Care and Use Committee.

Skeletal preparation, β-galactosidase staining and whole-mount in situ hybridization
Skeletal preparation and measurement, whole-mount β-galactosidase staining using X-Gal, whole-mount in situ hybridization were performed as described (Jin et al., 2011). The stained embryos were processed for cryosections. Fetuses/embryos and the cryosections were processed for cryosections. Fetuses/embryos and the cryosections were photographed using a Zeiss Stemi SV6 stereomicroscope and Zeiss AxioCam digital camera.

Scanning electron microscopy
Embryos were fixed with 2% glutaraldehyde/2% paraformaldehyde in PBS buffer followed by Oso4 and gradually dehydrated in ethanol. The embryos were critical point dried under CO2 and sputter coated with 30 nm gold particles. Images were obtained using an AMRay 10000 scanning electron microscope (Gold International Machinery) and xRF digital capture system at the Scanning Electron Microscopy Facility of the University of Maine at Orono.

BrdU incorporation and apoptosis assays and immunofluorescence staining
For BrdU incorporation assays, pregnant mice (E10.5 or E13.5) were intraperitoneally injected with BrdU (100 mg/kg body weight, Invitrogen) for 15 (E10.5-11 embryos) or 30 (E13.5 embryos) minutes prior to sacrifice. The incorporated BrdU was detected immunohistochemically in cryosections using a cell proliferation kit (Invitrogen). Apoptotic cells were detected in TdT-mediated dUTP nick-end labeling (TUNEL) assay using an in situ cell death detection kit (Roche Applied Science). Immunofluorescence staining with anti-phospho-histone H3 (1:100 dilution, Cell Signaling), anti-activated caspase 3 (1:100, Cell Signaling) and anti-PY489-β-catenin (1:100, Developmental Studies Hybridoma Bank) was performed on cryosections.

qRT-PCR and western blot analysis
Total RNA was isolated at least in triplicate from NP/MxP tissues freshly dissected from embryos and from cultured NP/MxP explants using Trizol (Sigma). Quantitative real-time (qRT) PCR using cDNA (10 ng total RNA equivalent) synthesized using the Proscript cDNA Synthesis Kit (New England Biolabs) was performed in duplicate per sample as described (Jin et al., 2011). Expression level was normalized to Gapdh and E-cadherin (Cdh1; when epithelium-specific genes were examined). PCR primers are listed in supplemental material Table S1 and as described previously (Jin et al., 2011).

Protein lysates (10 µg), prepared by homogenizing the tissues or cultured cells in RIPA lysis buffer [10 mM Tris-Cl pH 7.2, 2 mM EDTA, 150 mM NaCl, 1% Nonitid P40, 0.1% SDS, 50 mM NaF, 1% sodium deoxycholate, 1 mM PMFS, 1× protease inhibitor mixture set V (EMD Chemicals), 0.2 mM sodium vanadate] were used in western blot analysis. Primary antibodies (all 1:1000 dilution) were against phospho-LRP6 (Cell Signaling), LRP6 (Santa Cruz Biotechnology), phospho-κ-JUN (Cell Signaling), phospho-JNK1/2 (Cell Signaling), JNK1/2 (Cell Signaling), phospho-ROCK2 (Abcam), ROCK2 (Santa Cruz Biotechnology), phospho-ERK1/2 (Cell Signaling), ERK1/2 (Cell Signaling) and α-tubulin (Santa Cruz Biotechnology). The horseradish peroxidase (HRP) signal conjugated with secondary antibodies was developed using the Super Signal West Dura Kit (Thermo Scientific/Pierce). The signals were quantified using ImageJ software, and each experiment was performed in triplicate.

RHOA family small GTPase assays
The small GTPase assay was performed using the RHOA and RAC1/CDC42 activation assay kit (Millipore) according to the manufacturer’s instructions. Briefly, NP/MxP tissues were dissected in cold PBS from E10.5 wild-type or mutant embryos (n=7) and homogenized in lysis buffer comprising 20 mM HEPES (pH 7.4), 50 mM NaF, 0.2 mM MgCl2, 20% glycerol, 0.1% Triton X-100, 1 mM PMFS, 1× protease inhibitor mixture set V (EMD Chemicals), 0.2 mM sodium vanadate] were used in western blot analysis. Primary antibodies (all 1:1000 dilution) were against phospho-LRP6 (Cell Signaling), LRP6 (Santa Cruz Biotechnology), phospho-κ-JUN (Cell Signaling), phospho-JNK1/2 (Cell Signaling), JNK1/2 (Cell Signaling), phospho-ROCK2 (Abcam), ROCK2 (Santa Cruz Biotechnology), phospho-ERK1/2 (Cell Signaling), ERK1/2 (Cell Signaling) and α-tubulin (Santa Cruz Biotechnology). The horseradish peroxidase (HRP) signal conjugated with secondary antibodies was developed using the Super Signal West Dura Kit (Thermo Scientific/Pierce). The signals were quantified using ImageJ software, and each experiment was performed in triplicate.

Palate shelf and facial process explant and primary mesenchymal cell culture
Palatal organ culture was performed as described (Jin et al., 2011). For facial process explant culture, NP/MxP tissues were dissected in cold PBS from E10.5 or E11.5 (for ex vivo NP/MxP fusion assay) embryos and cultured for up to 36 hours on filters floating in Transwell plates (Corning) filled with αMEM medium with 0.1 µg/ml ascorbic acid, 10% fetal bovine serum (FBS) and streptomyacin/penicillin. When indicated, the ectodermal layer was removed by incubating the explants with dispase II (2.4 units/ml, Roche Applied Science) for 30 minutes.

Mesenchymal cells of the facial processes were prepared and cultured as previously described (Song et al., 2009) with minor modifications. After the ectodermal layer was removed by dispase II treatment, the NP/MxP mesenchymal tissues were digested in 0.25% trypsin solution on ice overnight. A single-cell suspension was obtained by gentle pipetting several times, and the cells were cultured in DMEM with 20% FBS. Recombinant
RESULTS

Wnt9b null mice display CL/P and skeletal abnormalities in the upper jaw

To determine the function of Wnt9b during facial development, we examined the craniofacial morphology of Wnt9b−/− mice at E18.5. Consistent with previous reports, Wnt9b−/− mice developed CL/P (unilateral CL/P, n=2/15; bilateral CL/P, n=13/15) (Fig. 1A-D), confirming that Wnt9b is required for proper development of the lip and palate. The penetrance of the CL/P phenotype in Wnt9b−/− mice was 100% in the mixed genetic background, which is higher than previously reported (Carroll et al., 2005; Juriloff et al., 2006), probably owing to different genetic backgrounds.

Histological analyses during palatogenesis showed that initial downward growth of the palatal shelves occurred normally in Wnt9b−/− mice at E12.5-13.5 (supplementary material Fig. S1E,F). A failure or delay of horizontal elevation of the palatal shelves that subsequently led to failed midline contact was observed in Wnt9b−/− mice at E14.5 (Fig. 1E,F). No apparent defects in cell proliferation (supplementary material Fig. S1A-C) or apoptosis (data not shown) within the palatal shelves or in their fusion ability (supplementary material Fig. S1G-J) were observed in Wnt9b−/− mice, indicating that palatogenesis defects in Wnt9b−/− mice are not intrinsic to the palatal shelves. These results are consistent with the absence of Wnt9b expression in the palate shelves (Lan et al., 2006; He et al., 2011).

We analyzed craniofacial bone and cartilage structures in Wnt9b−/− mice at E18.5. There was no obvious difference in the dimension of the skull, including length and width, in Wnt9b−/− mice (Fig. 1G,H; supplementary material Fig. S2). However, several skeletal components of the upper jaw were either missing or malformed (Fig. 1I-L). For instance, the premaxilla (pmx) of Wnt9b−/− mice was much smaller than that of wild-type mice and failed to connect. The palatine processes of both premaxilla and maxilla (pppx and ppmx) were underdeveloped and remained unfused (n=12/12). Interestingly, although some Wnt9b−/− mice displayed unilateral cleft lip, their primary palate skeleton, including ppmx and ppmx, was defective bilaterally. Taken together, loss of Wnt9b caused CL/P with developmental defects of the upper jaw skeleton.

Loss of Wnt9b causes reduced outgrowth and contact failure of the NP and MxP

The upper lip in mice is formed by a coordinated outgrowth and fusion of the MxP of BA1 with the LNP and MNP by E11.5. To investigate whether developmental defects of these processes are...
associated with CL/P in Wnt9b−/− mice, embryos were examined by scanning electron microscopy. No morphological defects were apparent in Wnt9b−/− embryos prior to E10.5. Reduced invagination of the nasal pit, especially near the posterior region, was seen at E10.5 (arrow in Fig. 2A,B; n=2). At E11, hypoplasia of the LNP and MNP became evident and the MNP failed to extend toward the LNP in Wnt9b−/− embryos, in contrast to wild-type embryos (Fig. 2C-F; n=2). Approximately half a day later in gestation, Wnt9b−/− embryos showed a clear bilateral gap between the MNP and the medial end of the fused LNP and MxP (Fig. 2G,H; n=2).

Reduced cell proliferation within the mesenchyme of the NP and MxP of Wnt9b−/− embryos

To investigate whether hypoplasia and failed fusion of the three processes were associated with specific cellular defects within the processes, we examined cell proliferation and apoptosis in Wnt9b−/− embryos. BrdU incorporation after pulse labeling and presence of phospho-histone H3, a marker for mitotic cells in G2/M phase, were used to assess cell proliferation. A significant reduction in the numbers of BrdU-positive and phospho-histone H3-positive cells was detected mainly in the mesenchymal compartment of both the NP and MxP of Wnt9b−/− embryos at E10.5 (Fig. 3).

Fig. 2. Scanning electron microscopy analysis of facial development. (A-H) Frontal views of wild-type (A,C,E,G) and Wnt9b−/− (B,D,F,H) mouse embryos from E10.5 to E11.5. The boxed regions in C and D are magnified in E and F, respectively. Reduced invagination between the MNP and LNP was clear in Wnt9b−/− embryos at E10.5 (arrow in B). At E11.0, hypoplasia of the MNP and LNP was obvious, and the MNP, LNP and MxP failed to complete fusion (arrows in D,F). At E11.5, bilateral lip clefts (arrows in H) were apparent in Wnt9b−/− embryos. Inp, lateral nasal process; mnp, medial nasal process; mxp, maxillary process.

In wild-type embryos, cell apoptosis examined by activated caspase 3 (aCasp3) immunostaining and TUNEL assay appeared to be a rare event within the processes (supplementary material Fig. S3A). Apoptosis was detected in the epithelial seam in the fusion zone of the MNP, LNP and MxP of wild-type embryos at E10.5 (arrow in supplementary material Fig. S3A). By contrast, no apoptosis was observed in the posterior tips (prospective fusion zone) of the MNP and LNP in Wnt9b−/− embryos at E10.5 (supplementary material Fig. S3B). However, despite the failed contact and fusion, some apoptosis was observed in the end region of the MNP and LNP of Wnt9b−/− embryos at E11, suggesting delayed development of the NPs and MxP (data not shown). Comparable results were obtained by TUNEL labeling (data not shown).

We further determined whether fusion between the NP and MxP is defective in Wnt9b−/− embryos. The NP and MxP dissected from Wnt9b−/− embryos at E11-11.5 efficiently fused (n=7/7) in ex vivo facial explant culture (supplementary material Fig. S3C-E).

Taken together, these results indicate that CL/P in Wnt9b−/− mice is likely to be caused by retarded and/or delayed outgrowth and subsequent failure of physical contact of the NP and MxP, primarily owing to the cell proliferation defect of mesenchymal cells.

WNT9B specifically regulates canonical WNT/β-catenin signaling within the NP and MxP

WNT9B activates both WNT/β-catenin and WNT/planar cell polarity (PCP) signaling during kidney development (Carroll et al., 2005; Karner et al., 2011) and in HEK293T cells (data not shown). To determine whether ablation of Wnt9b attenuates WNT/β-catenin signaling within craniofacial structures, we examined expression of a WNT/β-catenin signaling reporter, TopGAL, in Wnt9b−/− embryos. At E10.5, TopGAL expression was significantly reduced in both surface ectodermal and underlying mesenchymal cells of the NPs and MxP in Wnt9b−/− mutants compared with wild-type embryos (black arrows in Fig. 4A-D), suggesting that Wnt9b expressed in ectoderm regulates WNT/β-catenin signaling in both ectodermal and mesenchymal cells of the NPs and MxP. Surprisingly, there was no reduction of TopGAL expression in the MxP of Wnt9b−/− embryos (white arrows in Fig. 4A,B), despite robust Wnt9b expression in the MxP ectoderm. This might explain why no mandible defect was observed in Wnt9b−/− mutants and also suggests that Wnt9b function in mandibular arch development is not essential, possibly being compensated by other WNT genes expressed in the MxP.

In addition, presence of the activated β-catenin protein, the phosphorylated LRP6 receptor and expression of Axin2 were severely reduced in these facial processes of Wnt9b−/− embryos (Fig. 4E-G and Fig. 7I). Expression of the WNT/β-catenin signaling target genes Msx1 and Msx2 (Song et al., 2009), which are expressed in mesenchymal cells within the NPs and MxP (Gauchat et al., 2000; Alappat et al., 2003; Ishii et al., 2005), was also reduced in Wnt9b−/− embryos (Fig. 4H-K and Fig. 7I).

To confirm that Wnt9b function is associated with WNT/β-catenin signaling, we treated the NP/MxP explants isolated from TopGAL transgenic embryos with recombinant WNT9B protein. The WNT9B protein effectively increased TopGAL transgene expression in both whole (ectoderm/mesenchyme) and mesenchymal explants (Fig. 5A-D). In similar explant cultures, WNT9B robustly activated expression of the WNT/β-catenin signaling targets Axin2, Msx1 and Msx2 and inhibited Raldh3 (Aldh1a3 – Mouse Genome Informatics), which is negatively
regulated by WNT/β-catenin signaling activity (Song et al., 2009) (Fig. 5E,F; supplementary material Fig. S4A). WNT9B also efficiently rescued the reduced Axin2, Msx1 and Msx2 expression in Wnt9b−/− explants (supplementary material Fig. S4A).

We next tested whether the defects associated with loss of Wnt9b are rescued in vivo by activation of β-catenin signaling. When LiCl, a GSK3β inhibitor that activates WNT/β-catenin signaling, was administered in utero, the elevated Raldh3 expression in Wnt9b−/− embryos (Fig. 5G,H) was effectively reversed (Fig. 5I,J). This rescue effect was further confirmed in NP/MxP tissues isolated from embryos after in utero LiCl administration by qRT-PCR, as reduced expression of Axin2, Msx1 and Msx2 and increased expression of Raldh3 in Wnt9b−/− embryos were reversed by LiCl (Fig. 5K). Taken together, these results confirmed that WNT/β-catenin signaling was severely compromised in the NPs and MxP of Wnt9b−/− embryos.

Fig. 3. Cell proliferation in the lip fusion zone. (A-D) Immunostaining for incorporated BrdU in the facial processes at E10.5. Note that the epithelial layer in the fusion area lacks BrdU-positive cells (arrows). (E-H) Mitotic cells detected by phospho-histone H3 in the facial processes at E10.5. The epithelial layer in the fusion area lacks phospho-histone H3-positive cells (arrows). (I,J) For calculating the proliferation rate, the numbers of BrdU-positive or phospho-histone H3-positive cells were counted in each of two sections of three embryos. Mean±s.e.m. *P<0.05, Student’s t-test. lnp, lateral nasal process; mnp, medial nasal process; mxp, maxillary process.

Fig. 4. Disruption of WNT/β-catenin signaling in Wnt9b−/− embryos. (A-D) TopGAL expression detected by colorimetric staining of β-galactosidase activity in wild-type and Wnt9b−/− mouse embryos. Black arrows indicate the NPs where significantly reduced TopGAL expression was observed in Wnt9b−/− embryos. There was no reduction of TopGAL expression in the MdP (white arrow in B). Dotted white lines in A and B indicate the plane of sections shown in C and D, respectively. Decreased TopGAL expression was apparent in both surface ectoderm and mesenchyme of the NPs (C,D). (E,F) Immunofluorescent staining of active β-catenin protein (green) in the facial processes at E11.0. (G) Western blot analysis of phosphorylated LRP6 in NP and MxP tissue lysates. Total LRP6 level provided a protein loading control. Signal levels from the triplicate samples were quantified using ImageJ and are presented as mean±s.e.m. *P<0.05, Student’s t-test. (H-K) Msx1 and Msx2 expression in E10.5-11 embryos was determined by whole-mount in situ hybridization. Arrowheads indicate the reduced expression domains in Wnt9b−/− embryos. mdp, mandibular process of branchial arch 1; lnp, lateral nasal process; mnp, medial nasal process; mxp, maxillary process.
Deletion of Wnt9b has no obvious effect on WNT/PCP signaling

To determine whether loss of Wnt9b influences non-canonical WNT/PCP signaling activity, we examined activation of RHOA, RAC1 and CDC42, three small GTPases key to the WNT/PCP pathway, in tissue lysates prepared from the NP and MxP of E10.5 embryos. No differences in the activation of these proteins were observed between wild-type and Wnt9b–/– mouse embryos, whereas black arrowheads (I,J) indicate suppression of the elevated Raldh3 expression by LiCl. Wnt9b–/– embryos at E10.5 was repressed by in utero LiCl administration. Red arrowheads (G,H) indicate elevated Raldh3 expression in Wnt9b–/– embryos, whereas black arrowheads (I,J) indicate suppression of the elevated Raldh3 expression by LiCl. Wnt9b–/– embryos after in utero LiCl administration. Total RNAs were isolated from the dissected NP and MxP tissues. Mean±s.e.m.*P<0.05, Student’s t-test.

WNT9B regulates FGF family gene expression within the ectoderm of the NP and MxP

It is well known that ectoderm-derived signals such as FGF, BMP and SHH regulate mesenchymal cell proliferation/survival and differentiation in the facial processes (Abu-Issa et al., 2002; Liu et al., 2005; Alkuraya et al., 2006; Riley et al., 2007). We found that there was significant downregulation of several FGF family genes within the facial processes in Wnt9b–/– embryos at E10.5-11 (Fig. 7), whereas Bmp4 and Shh expression was not modified (supplementary material Fig. S5). Expression of Fgf8, Fgf10 and Fgf17 was either absent or severely reduced in the LNP and MNP at E10.5 (Fig. 7A-I). Additionally, Fgf8 and Fgf10 expression remained reduced in the NPs of Wnt9b–/– embryos at E11 (Fig. 7C,D; data not shown).

To determine whether these FGF genes are regulated by WNT/β-catenin signaling activated by WNT9B, we examined their expression in the NP/MxP explants treated with WNT9B protein. WNT9B significantly induced the expression of three FGF genes in wild-type explants and effectively reversed the reduced FGF gene expression in Wnt9b–/– explants (supplementary material Fig. S4A). Consistent with these results, reduced FGF expression in Wnt9b–/– embryos was efficiently reversed by in utero treatment with LiCl (supplementary material Fig. S4B). We next examined FGF gene expression in E10.5 embryos in which β-catenin is constitutively activated within the ectoderm of the NP and MxP by Foxg1-Cre-mediated recombination of the Cmmnt1loxPEx3 allele (Harada et al., 1999). All three FGF genes, as well as Axin2, were highly induced by activated β-catenin, whereas Raldh3 expression decreased (Fig. 7J).

Ectodermal FGFs induced by Wnt9b regulate proliferation of facial process mesenchymal cells

To determine whether reduced ectodermal FGF gene expression resulted in a decrease in FGF signaling in the facial processes, we examined phosphorylation of ERK1/2 (MAPK3/1–Mouse

Fig. 5. Ex vivo activation of WNT/β-catenin signaling in the NP and MxP by WNT9B protein and in vivo activation of WNT/β-catenin signaling by LiCl in Wnt9b–/– embryos. (A–D) Ex vivo facial explant culture. A pair of NP/MxP explants was dissected from the same TopGAL mouse embryo at E10.5 and cultured in the absence or presence of recombinant WNT9B protein (800 ng/ml) for up to 36 hours. Either whole (ectoderm plus mesenchyme, A,B) or mesenchyme (C,D) explants were cultured and stained for β-galactosidase activity. (E,F) qRT-PCR analysis of gene expression in the NP/MxP explants cultured in the absence or presence of WNT9B. The relative expression level compared with the control Wnt9b–/– gene expression in the NP/MxP explants cultured in the absence or presence of WNT9B. The relative expression level compared with the BSA-treated control samples is presented as mean±s.e.m.*P<0.05, **P<0.01, ***P<0.005, Student’s t-test. (G–J) Elevated Raldh3 expression in the facial processes of Wnt9b–/– embryos at E10.5 was repressed by in utero LiCl administration. Red arrowheads (G,H) indicate elevated Raldh3 expression in Wnt9b–/– embryos, whereas black arrowheads (I,J) indicate suppression of the elevated Raldh3 expression by LiCl. Wnt9b–/– embryos after in utero LiCl administration. Total RNAs were isolated from the dissected NP and MxP tissues. Mean±s.e.m.*P<0.05, Student’s t-test. mdp, mandibular process of branchial arch 1; lnp, lateral nasal process; mnp, medial nasal process; mxp, maxillary process; TopGAL, mouse embryo at E10.5 and cultured in the absence or presence of recombinant WNT9B protein (800 ng/ml) for up to 36 hours. Either whole (ectoderm plus mesenchyme, A,B) or mesenchyme (C,D) explants were cultured and stained for β-galactosidase activity. (E,F) qRT-PCR analysis of gene expression in the NP/MxP explants cultured in the absence or presence of WNT9B. The relative expression level compared with the BSA-treated control samples is presented as mean±s.e.m.*P<0.05, **P<0.01, ***P<0.005, Student’s t-test. (G–J) Elevated Raldh3 expression in the facial processes of Wnt9b–/– embryos at E10.5 was repressed by in utero LiCl administration. Red arrowheads (G,H) indicate elevated Raldh3 expression in Wnt9b–/– embryos, whereas black arrowheads (I,J) indicate suppression of the elevated Raldh3 expression by LiCl. Wnt9b–/– embryos after in utero LiCl administration. Total RNAs were isolated from the dissected NP and MxP tissues. Mean±s.e.m.*P<0.05, Student’s t-test. mdp, mandibular process of branchial arch 1; lnp, lateral nasal process; mnp, medial nasal process; mxp, maxillary process.
We next investigated whether WNT9B and FGFs are mitogenic for facial process mesenchymal cells. WNT9B treatment did not enhance the proliferation of mesenchymal cells isolated from the NP and MxP of E10.5 embryos (Fig. 8E). By contrast, both FGF8 and FGF10 efficiently enhanced proliferation of these cells (Fig. 8F). Furthermore, proliferation of mesenchymal cells prepared from Wnt9b−/− embryos was also enhanced by FGFs to a level comparable to wild-type cells (Fig. 8F).

We also examined whether the FGF and WNT9B proteins have any effect on mesenchymal cell migration. The migratory behavior of mesenchymal cells in wound-healing and Transwell cell migration assays were unaffected by FGF or WNT9B (supplementary material Fig. S6).

Taken together, we conclude that WNT9B positively regulates FGF gene expression in the ectoderm of the NP and MxP, and that WNT9B-induced ectodermal FGF signaling is required for the proliferation of mesenchymal cells within the NPs and MxP (Fig. 8G).

**DISCUSSION**

**Wnt9b controls outgrowth of facial processes through the canonical WNT/β-catenin pathway**

The primary embryonic defect of facial development in Wnt9b−/− mutants is hypoplasia with reduced outgrowth of the NPs and MxP (Fig. 2) as a direct consequence of reduced proliferation (Fig. 3). A subsequent failure of physical contact between the LNP and MNP at ~E10-11.5 prevents fusion between the facial processes (Fig. 2) and eventually results in cleft lip with cleft palate at later stages in Wnt9b−/− mice (Fig. 1). Several lines of evidence confirm that these cellular defects result from compromised WNT/β-catenin signaling. A significant reduction in active β-catenin protein accumulation, in phosphorylation of the LRP6 receptor and in expression of WNT/β-catenin signaling reporter and downstream target genes in the NP and MxP were observed in Wnt9b−/− embryos (Figs 4, 5). The recombinant WNT9B protein effectively increased WNT/β-catenin signaling in facial process explant cultures in vitro (Fig. 5). Furthermore, in utero LiCl treatment partially restored β-catenin activation in Wnt9b null embryos as assessed by target gene expression at E10.5-11 (Fig. 5G-K; supplementary material Fig. S4B). However, morphological defects, when observed in E13.5 embryos, were not rescued by in utero LiCl administration (data not shown), suggesting that the LiCl administration scheme (timing, dosage and frequency) might not be optimal for phenotypic rescue. Additionally, because GSK3β also plays a key role in the negative regulation of SHH signaling through the phosphorylation of the GLI2/3 transcription factors (Lum and Beachy, 2004), in utero LiCl treatment can activate SHH signaling simultaneously. A genetic approach to WNT signaling activation or the use of a more specific WNT signaling activator is warranted to determine whether the defects in Wnt9b−/− embryos can be rescued by activation of β-catenin signaling.

Consistent with the phenotypes of Wnt9b mutants, Lrp6 mutant mice show a full penetrance of CL/P with retarded outgrowth of the NP and MxP (Song et al., 2009). In these mutant mice, severely reduced proliferation without apparent apoptosis is evident in mesenchymal cells of the NP and MxP (Song et al., 2009). Moreover, WNT9B protein has been shown to directly bind to the extracellular domain of the LRPs receptor using an in vitro protein interaction assay (Bourhis et al., 2010; Gong et al., 2010), strongly suggesting that WNT9B transmits its signal through the LRPs receptor in the facial processes.
Ectoderm-specific inactivation and activation of Ctnnb1 in the facial processes caused severe hypoplasia and hyperplasia of the facial processes, respectively (Reid et al., 2011; Wang et al., 2011). Mesenchymal-specific Ctnnb1 deletion in the facial processes also causes severe defects in facial development, with missing facial skeletal components accompanying significant hypoplasia in the frontofacial region and BA1 (Brault et al., 2001). Interestingly, unlike Wnt9b and Lrp6 mutants, increased apoptosis without reduced proliferation was detected in both ectodermal and mesenchymal cells of the BA1 and NPs of Ctnnb1 deletion mutants (Brault et al., 2001; Wang et al., 2011). Inactivation of Wnt9b or Lrp6 might only partially remove the activity of WNT/β-catenin signaling in the facial processes, as Lrp5 and other WNT genes can provide the remaining WNT signaling activity. Different cellular defects (proliferation versus apoptosis) observed in mice lacking Ctnnb1, Lrp6 or Wnt9b also strongly suggest that multiple cellular processes are regulated by WNT/β-catenin signaling within the facial processes.

**WNT9B cannot activate non-canonical WNT/PCP signaling during facial development**

A previous study demonstrated that Wnt9b also acts through the non-canonical WNT/PCP pathway, mainly the RHOA-JNK signaling cascade, during kidney development (Kamer et al., 2009). In contrast to kidney development, we failed to detect any indication of reduced (or induced) WNT/PCP signaling in the facial processes of Wnt9b−/− embryos (Fig. 6). In general, there is scant WNT/PCP signaling activity within these processes in wild-type embryos.

Consistent with this notion, ectoderm- and mesenchymal-specific deletion of Rac1, Cdc42 or Rhoa in the facial processes does not result in any notable phenotypic defects in facial structures until E10.5 (Chen et al., 2006; Fuchs et al., 2009; Thomas et al., 2010; Katayama et al., 2011). No morphological hypoplasia was found in the NP and MxP of mesenchyme-specific Rac1 and Cdc42 mutant mice at E11 (Fuchs et al., 2009; Thomas et al., 2010). Severe malformations of neural crest-derived structures and mid-facial cleft appeared in these mutants at ~E11.5.

Mice lacking both the Fzd1 and Fzd2 receptor genes exhibit signatures of defective WNT/PCP signaling, including a failure of closure in the palate, ventricular septum and neural tube, and misorientation of inner ear sensory hair cells (Yu et al., 2010). However, these mice still display normal development of the NP and MxP and lip fusion. Taken together, our results and previously published reports suggest that non-canonical WNT/PCP signaling plays insignificant or minimal roles within the NPs and MxP during the stage when the defects associated with Wnt9b null mutation are apparent.

**WNT/β-catenin signaling is required for FGF gene expression in facial process ectoderm to induce mesenchyme cell proliferation**

Reduced cell proliferation in mesenchymal cells of the facial processes in Wnt9b−/− embryos raises the question of whether ectoderm-derived WNT9B ligand can act as a mitogen for mesenchymal cells. The recombinant WNT9B protein failed to induce proliferation of primary facial mesenchyme cells in culture (Fig. 7), indicating that WNT9B might not be a mitogen that induces mesenchyme cell proliferation. Given the evident reduction of WNT/β-catenin signaling activity within the ectodermal layer of the NP and MxP in Wnt9b null mutants, it is plausible that WNT9B might induce ectoderm-derived mitogens.

It is known that FGF signaling plays crucial roles in facial development. Among 22 FGF genes, at least seven (Fgf3, Fgf8, Fgf9, Fgf10, Fgf15, Fgf17 and Fgf18) are expressed with a regional specificity within the ectoderm of the facial processes in mice between E9.5 and E10.5 (Bachler and Neubuser, 2001). We found that Fgf10, Fgf17 RNA expression and FGF-induced phosphorylation of ERK1/2 were significantly reduced in the NP and MxP of Wnt9b−/− embryos (Figs 7, 8). Ectoderm-specific activation of β-catenin in the facial processes resulted in increased expression of these FGF genes (Fig. 7M), strongly suggesting that they are targets for WNT/β-catenin signaling. Indeed, Fgf8 and Fgf10 were previously identified as direct WNT/β-catenin target genes in facial and cardiac tissues, respectively (Cohen et al., 2007; Wang et al., 2011).
The cellular consequence of reduced FGF signaling in the facial processes in mice deficient of Wnt9b/β-catenin signaling remains unclear. BA1 ectoderm-specific Fgf8 deletion studies have shown that ectodermal FGF signaling is mainly required for mesenchymal cell survival in BA1 (Trumpp et al., 1999), whereas reduced cell proliferation is a major response affected by reduced FGF signaling in the NP and MxP of Wnt9b−/− mouse embryos. Immunostained images (A, B) and their quantitation (C) are presented. (D) Activation of ERK1/2 phosphorylation by FGF8 and FGF10. The upper facial mesenchymal cells were stimulated with FGFs or WNT9B for 5 or 15 minutes. NP603 (5 μM) was added to the cells simultaneously with FGFs. Total and phosphorylated ERK1/2 protein levels were analyzed by western blot. (E,F) Mesenchymal cell proliferation was enhanced by FGF8 and FGF10 but not WNT9B. Mesenchymal cells isolated from the wild-type or Wnt9b−/− NP/MxP explants were cultured in the presence of FGFs or WNT9B for 3 days. Total cell numbers were counted. Mean±s.e.m. *P<0.05, **P<0.01, Student’s t-test. (G) Model for WNT9B function in upper facial development. The facial ectoderm-derived WNT9B regulates the FGF family genes and Raldh3 in ectoderm and the Mxst1/2 genes in mesenchyme in a β-catenin-dependent manner. Cell proliferation within mesenchyme is directly regulated by WNT9B-induced FGFs. Epi, epithelium; Ect, surface ectoderm; Mes, mesenchyme; Inp, lateral neural process; mnp, medial neural process.

Another possibility is a differential tissue response to FGFs. FGF signaling primarily controls cell survival in the MdP and telenephalon (Trumpp et al., 1999; Paek et al., 2009; Paek et al., 2011). Ablation of Cninβ1 in the facial ectoderm induces more significant cell death in BA1 than in the NPs (Reid et al., 2011), suggesting that there might be a differential response to FGF signaling in these cells. These observations, including our present findings, suggest the interesting possibility that fine-tuned FGF signaling activity differentially regulates two distinct cellular behaviors, i.e. proliferation and survival, within the facial processes.

Acknowledgements
The authors declare no competing financial interests.

Supplementary material
Supplementary material available online at http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.075796/-/DC1

References


Jin et al., Fig. S1

**Figure S1**

(A and B) Comparison of E13.5 lateral somitic mesenchyme (ps) and tail (t) sections from wild-type (Wnt9b<sup>wt/wt</sup>) and Wnt9b<sup>−/−</sup> embryos. Scale bar: 0.2 mm.

(C) BrdU<sup>+</sup> cell percentages in somitic mesenchyme (Mes) and epidermis (Epi) from E13.5-14.0 wild-type and Wnt9b<sup>−/−</sup> fetus. 24 to 48 hour culture.

(D and E) Sections from E14.0 wild-type and Wnt9b<sup>−/−</sup> embryos. Scale bar: 0.5 mm.

(F) Diagram showing E13.5-14.0 fetus with somitic mesenchyme (ps) and epidermis (Epi) sections.
WNT9B Con
0
50
100
150 Migrated cells/Fixed area

Transwell Migration Assay

Jin et al., Fig. S6

Wound Healing Cell Migration Assay

BSA WNT9B (400ng/ml)

FGF8 (400ng/ml) FGF10 (400ng/ml)

20 μm

E

Transwell Migration Assay

Migrated cells/Fixed area

Con WNT9B
The primer sequences for Axin2, Msx1, Msx2, Fgf8 and Gapdh were described previously (Jin et al., 2011).

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer</th>
<th>Sequence (5’ to 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fgf10</td>
<td>Sense</td>
<td>AAGAATGAAGACTGTCCGTACAGTGTCC</td>
</tr>
<tr>
<td></td>
<td>Antisense</td>
<td>GCTTACAGTCGTTGTTAAACTCTTTTGAGC</td>
</tr>
<tr>
<td>Fgf17</td>
<td>Sense</td>
<td>AGAGGATGGCAACAAGTTTGCGCAAG</td>
</tr>
<tr>
<td></td>
<td>Antisense</td>
<td>AGTCTTTGCTCTCCCGCTCGGCTTG</td>
</tr>
<tr>
<td>Raldh3</td>
<td>Sense</td>
<td>AGCCTCTCTCATCAAAGAGGTCGG</td>
</tr>
<tr>
<td></td>
<td>Antisense</td>
<td>CTCTGACCAGCTTCTCAAACCTCTG</td>
</tr>
<tr>
<td>E-cadherin</td>
<td>Sense</td>
<td>TCATGGATCAGAAGATCACGTATC</td>
</tr>
<tr>
<td></td>
<td>Antisense</td>
<td>AGTGGCAATGGGTGAACCATCATC</td>
</tr>
</tbody>
</table>